The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries.

ABSTRACT:

Background and aims

We assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain.

Methods

An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus disease (COVID-19) was also developed.

Results

The estimated number of avoided hepatocellular carcinoma, decompensated cirrhosis and liver transplantations over a 20-year time horizon was: 1,057 in England; 1,221 in Italy; 1,211 in Romania; and 1,103 in Spain

SUBMITTER: Mennini FS 

PROVIDER: S-EPMC8248004 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature